Advertisement
U.S. markets closed

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.37-0.08 (-0.71%)
At close: 01:08PM EST
11.11 -0.26 (-2.28%)
After hours: 08:00PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Pharming Group to report fourth quarter and full year 2023 financial results on March 14

    Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.To participate in the conference call, please register in advance using the link below. Once registered, dial-

  • GlobeNewswire

    Pharming Group to participate in February investor conferences

    Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of February: Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference, February 13-14, 2024Sijmen de Vries, Chief Executive Officer, will present on Tuesday, February 13 at 11:20 ET/17:20 CET. A live webcast and replay of the presentation will be available in the “Up

  • GlobeNewswire

    Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

    Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the full year 2023